Work at the Karolinska Institutet has revealed a potential new therapeutic target in type 2 diabetes.
How can cells be insulin resistant and insulin sensitive at the same time?
Uncovering what’s behind this phenomenon could help lead to new treatments for type 2 diabetes (T2D), so researchers from the Karolinska Institutet of Sweden have been at work, searching for an explanation.
Barbara Leibiger, PhD, and Ingo Leibiger, PhD, both with the Department of Molecular Medicine and Surgery at the Karolinska Institutet, have published research Cell Reports on their work with insulin-producing beta cells that uncovers a mechanism behind the mystery.
Those with T2D suffer insulin resistance, which means their cells and organs are insensitive to insulin; persons with this condition respond by increasing the number of insulin-producing cells to hold blood glucose in check.
The Leibigers had previously shown that beta cells have 2 receptors with separate biological functions, insulin receptor A and insulin receptor B. In the new study, they report that when a person has diabetes, insulin receptor B can be insulin insensitive on one pathway, but that doesn’t stop insulin from activating the other pathway, which causes the beta cells to increase.
The factor that causes this switching mechanism is PI3K-C2α, which could represent a therapeutic target for future treatments.
"The results are important since it explains how the beta cell can go from a differentiated state to a proliferative state", says Ingo Leibiger. "This means that the cells change from being glucose-responsive to instead increase in number."
Reference
Leibiger B, Moede T, Paschen M, et al. PI3K-C2α knockdown results in rerouting of insulin signaling and pancreatic beta cell [published online September 17, 2015]. Cell Reports. 2015; http://www.cell.com/cell-reports/abstract/S2211-1247(15)00955-9.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More